Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study

The Lancet Rheumatology 2026

View at publisher
Authors: Mikkel Østergaard, Espen A Haavardsholm, Miroslawa Nowak, Yi Luo, Jessica Landis, Aberra Fura, Chahin Pachaï, Duncan Rotich, Yanlin Wang-Fischer, Leonidas N. Carayannopoulos, David Zammit, Hazem Karabeber
+2 more Alice Wang, Dennis M. Grasela
DOI: 10.1016/s2665-9913(25)00374-1
Cited by: 1
References: 30

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Rheumatoid Arthritis Research and Therapies HER2/EGFR in Cancer Research

Publication details

Journal / source
The Lancet Rheumatology
Publisher
Elsevier BV
Volume
8
Issue
7
Pages
e539–e549
Publication date
1 May 2026
Language
EN